High throughput screening for small molecule inhibitors of heparin-induced tau fibril formation
- 22 June 2007
- journal article
- Published by Elsevier BV in Biochemical and Biophysical Research Communications
- Vol. 358 (1), 1-6
- https://doi.org/10.1016/j.bbrc.2007.03.056
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- NEURODEGENERATIVE DISEASES: New Concepts of Pathogenesis and Their Therapeutic ImplicationsAnnual Review Of Pathology-Mechanisms Of Disease, 2006
- Microtubule-stabilising drugs for therapy of Alzheimer’s disease and other neurodegenerative disorders with axonal transport impairmentsExpert Opinion on Pharmacotherapy, 2005
- Inhibition of Heparin-induced Tau Filament Formation by Phenothiazines, Polyphenols, and PorphyrinsPublished by Elsevier BV ,2005
- Protein aggregation and neurodegenerative diseaseNature Medicine, 2004
- Small-molecule inhibitors of protein–protein interactions: progressing towards the dreamNature Reviews Drug Discovery, 2004
- Ligand-Dependent Inhibition and Reversal of Tau Filament FormationBiochemistry, 2004
- Identification of a novel class of orally active pyrimido[5,4-3][1,2,4]triazine-5,7-diamine-based hypoglycemic agents with protein tyrosine phosphatase inhibitory activityBioorganic & Medicinal Chemistry Letters, 2003
- A Specific Mechanism of Nonspecific InhibitionJournal of Medicinal Chemistry, 2003
- A Common Mechanism Underlying Promiscuous Inhibitors from Virtual and High-Throughput ScreeningJournal of Medicinal Chemistry, 2002
- Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines.Proceedings of the National Academy of Sciences of the United States of America, 1996